Serum levels of tenascin-C in collagen diseases

Journal of Dermatology

Volumn 40, Issue 9, 2013, Pages 715-719

  Inoue, Kuniko ^a   Jinnin, Masatoshi ^a   Hara, Yumiko ^a   Makino, Katsunari ^a   Kajihara, Ikko ^a   Makino, Takamitsu ^a   Sakai, Keisuke ^a   Fukushima, Satoshi ^a   Inoue, Yuji ^a   Ihn, Hironobu ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

autoimmune disease; dermatomyositis; fibrosis; scleroderma; systemic lupus erythematosus

Indexed keywords

ANTINUCLEAR ANTIBODY; TENASCIN;

ADULT; AGED; ARTICLE; COLLAGEN DISEASE; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE DURATION; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART RIGHT VENTRICLE PRESSURE; HUMAN; LOCALIZED SCLERODERMA; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MOLECULAR WEIGHT; ONSET AGE; PATHOGENESIS; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SCLERODERMA; SCLERODERMA SPECTRUM DISORDER; SKIN PIGMENTATION; SKIN SCAR; SKIN ULCER; SKINFOLD THICKNESS; SYSTEMIC LUPUS ERYTHEMATOSUS;

AUTOIMMUNE DISEASE; DERMATOMYOSITIS; FIBROSIS; SCLERODERMA; SYSTEMIC LUPUS ERYTHEMATOSUS;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CONNECTIVE TISSUE DISEASES; FEMALE; HUMANS; MIDDLE AGED; TENASCIN;

EID: 84883561037     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.12218     Document Type: Article

References (24)

1. van de Loo FA, van den Berg WB,. Immunocytokines: the long awaited therapeutic magic bullet in rheumatoid arthritis? Arthritis Res Ther 2009; 11: 132.
2. Ihn H,. Scleroderma, fibroblasts, signaling, and excessive extracellular matrix. Curr Rheumatol Rep 2005; 7: 156-162.
3. Mochimaru H, Kawamoto M, Enomoto T, et al,. Transbronchial biopsy is clinically useful in classifying patients with interstitial pneumonia associated with polymyositis and dermatomyositis. Respirology 2008; 13: 863-870.
4. Chiquet-Ehrismann R,. Tenascins. Int J Biochem Cell Biol 2004; 36: 986-990.
5. Jones FS, Jones PL,. The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. Dev Dyn 2000; 218: 235-259.
6. Tanaka H, El-Karef A, Kaito M, et al,. Circulating level of large splice variants of tenascin-C is a marker of piecemeal necrosis activity in patients with chronic hepatitis C. Liver Int 2006; 26: 311-318.
7. Hasegawa M, Hirata H, Sudo A, et al,. Tenascin-C concentration in synovial fluid correlates with radiographic progression of knee osteoarthritis. J Rheumatol 2004; 31: 2021-2026.
8. Latijnhouwers MA, de Jongh GJ, Bergers M, et al,. Expression of tenascin-C splice variants by human skin cells. Arch Dermatol Res 2000; 292: 446-454.
9. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23: 581-590.
10. Hochberg MC,. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
11. LeRoy EC, Black C, Fleischmajer R, et al,. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-205.
12. Ihn H, Sato S, Tamaki T, et al,. Clinical evaluation of scleroderma spectrum disorders using a points system. Arch Dermatol Res 1992; 284: 391-395.
13. Mizutani H, Taniguchi H, Sakakura T, et al,. Nodular scleroderma: focally increased tenascin expression differing from that in the surrounding scleroderma skin. J Dermatol 1995; 22: 267-271.
14. Varga J, Rudnicka L, Uitto J,. Connective tissue alterations in systemic sclerosis. Clin Dermatol 1994; 12: 387-396.
15. Bohan A, Peter JB,. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-347.
16. Bohan A, Peter JB,. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 403-407.
17. Hisatomi K, Sakamoto N, Mukae H, et al,. Elevated levels of tenascin-C in patients with cryptogenic organizing pneumonia. Intern Med 2009; 48: 1501-1507.
18. Maricq HR, Weinrich MC, Keil JE, et al,. Prevalence of scleroderma spectrum disorders in the general population of South Carolina. Arthritis Rheum 1989; 32: 998-1006.
19. Maricq HR, McGregor AR, Diat F, et al,. Major clinical diagnoses found among patients with Raynaud phenomenon from the general population. J Rheumatol 1990; 17: 1171-1176.
20. Schumann C, Lepper PM, Frank H, et al,. Circulating biomarkers of tissue remodelling in pulmonary hypertension. Biomarkers 2010; 15: 523-532.
21. Sato A, Hiroe M, Akiyama D, et al,. Prognostic value of serum tenascin-C levels on long-term outcome after acute myocardial infarction. J Card Fail 2012; 18: 480-486.
22. Siri A, Knäuper V, Veirana N, et al,. Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases. J Biol Chem 1995; 270: 8650-8654.
23. Korn JH,. Immunologic aspects of scleroderma. Curr Opin Rheumatol 1989; 1: 479-484.
24. LeRoy EC, Medsger TA,. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-1576.